Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAFV600E–mutant metastatic colorectal cancer (mCRC), after progression on 1-2 prior regimens. In the previously reported primary ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, Josep, Grothey, Axel, Van Cutsem, Eric, Yaeger, Rona, Wasan, Harpreet, Yoshino, Takayuki, Desai, Jayesh, Ciardiello, Fortunato, Loupakis, Fotios, Hong, Yong Sang, Steeghs, Neeltje, Guren, Tormod Kyrre, Arkenau, Hendrik-Tobias, Garcia-Alfonso, Pilar, Elez, Elena, Gollerkeri, Ashwin, Maharry, Kati, Christy-Bittel, Janna, Kopetz, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078423/
https://www.ncbi.nlm.nih.gov/pubmed/33503393
http://dx.doi.org/10.1200/JCO.20.02088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078423/
https://www.ncbi.nlm.nih.gov/pubmed/33503393
http://dx.doi.org/10.1200/JCO.20.02088

Ejemplares similares